Preclinical trials - An update on translational research in ALS

Neurodegenerative Diseases

Volumn 2, Issue 3-4, 2006, Pages 215-219

  Ludolph, Albert C ^a   Sperfeld, A D ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

ALS, clinical trials; ALS, translational research; Dynein dynactin; Motor neuron disease; Motor neuron diseases, animal models; Motor neuron diseases, experimental therapies

Indexed keywords

ALPHA TOCOPHEROL; CEPHALOSPORIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DYNACTIN; DYNEIN ADENOSINE TRIPHOSPHATASE; GABAPENTIN; GLATIRAMER; MINOCYCLINE; MOLECULAR MOTOR; PENTOXIFYLLINE; RASAGILINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TREATMENT FAILURE; EXPECTATION; GENDER; GENE MUTATION; HUMAN; HYPOTHESIS; MEDICAL RESEARCH; METHODOLOGY; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY FAILURE; REVIEW; RNA TRANSLATION; STANDARD; STANDARDIZATION; SURVIVAL; TRANSGENIC ANIMAL; VALIDATION PROCESS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MICE; RESEARCH DESIGN;

EID: 33744786331     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000089628     Document Type: Review

References (31)

1. Van Gijn J: Pioneers in neurology: the Vogts: Cécile (1875-1962) and Oskar (1870-1959). J Neurol 2003;250:1261-1262.
2. Vogt C, Vogt O: Sitz und Wesen der Krankheiten I. J Psychol Neurol 1937;47:237-457.
3. Vogt C, Vogt O: Sitz und Wesen der Krankheiten II. J Psychol Neurol 1938;48:169-324.
4. Rosen DR, Siddique T, Patterson D, et al: Mutations in the CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
5. Gurney ME, Pu H, Chiu AY, et al: Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
6. Philips GC, Porter R: Corticospinal Neurones: Their Role in Movement. London, Academic Press, 1977.
7. Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
8. Rothstein J: Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 2003;53:423-426.
9. Heimann-Patterson TD, Deitch JS, Blankenhorn E, et al: Background and gender effects on survival in the SOD1 (G93A) transgenic model of ALS. J Neurol Sci 2005;236:1-7.
10. Angelov DN, Waibel S, Guntinas-Lichius O, et al: Therapeutic vaccine for acute and chronic motor neuron diseases: implications for ALS. Proc Natl Acad Sci USA 2003;100:4790-4795.
11. Schwalenstöcker B, Danzeisen R, Ludolph AC: Copaxone treatment in a mouse model of ALS: effect of gender and genetic background. Amyotroph Lateral Scler Other Motor Neuron Dis 2004;5(suppl 2):91-92.
12. Kipnis J, Schwartz M: Dual activation of glatiramer acetate (COP-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med 2002;8:319-323.
13. Klivenyi P, Ferrante RJ, Matthews RT, et al: Neuroprotective effect of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
14. Groeneveld GJ, Veldink H, Van der Tweel I, et al: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
15. Van den Bosch L, Tilkin P, Lemmens G, Robberecht W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-1070.
16. Gurney ME, Cutting FB, Zhai P, et al: Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157.
17. Bensimon G, Lacomblez L, Meininger V, and the Riluzole Study Group: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-589.
18. Lacomblez L, Bensimon G, Leigh PN, et al for the amyotrophic lateral sclerosis/riluzole study group: dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
19. Waibel S, Reuter A, Malessa S, et al: Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004;251:1080-1084.
20. Schwalenstöcker B, Kussmaul L, Danzeisen R, et al: The (+) enantiomer of pramipexole (SND919CL2X) prolongs survival and preserves motor function in a mouse model of familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Dis 2003;4(suppl 1):141.
21. Meininger V, Asselain B, Guillet P, et al: Pentoxyphyllin in amyotrophic lateral sclerosis. A double-blind, multicentre, placebo-controlled trial. Lessons for future trials. Lancet Neurology, in press.
22. Desnuelle C, Dib M, Garrel C, et al: A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Dis 2001;2:9-18.
23. Graf M, Ecker D, Horowski R, et al: High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112:649-660.
24. Miller RG, Moore DH, Gelinas DF: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848.
25. Petri S, Kiaei M, Kipiani K, et al: Pentoxyphyllin and revimide block TNF-α-mediated motor neuron death in a transgenic mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Dis 2004;5(suppl 2):14-15.
26. Hanemann CO, Ludolph AC: Motor proteins in diseases of the nervous system. Amyotroph Lateral Scler Other Motor Neuron Dis, in press.
27. Hafezparast M, Klocke R, Ruhrberg C, et al: Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003;300:808-812.
28. Puls I, Jonnakuty C, LaMonte BH, et al: Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-456.
29. Münch C, Sedlmeier R, Meyer T, et al: Point mutations of the p150 subunit of dynactin (DCTNI) gene in amyotrophic lateral sclerosis. Neurology 2004;63:724-726.
30. Fisher EMC, Ahmad-Annuar A, Shah P, et al: No association with genotypes in exons 8, 13 and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1) and familial motor neuron disorders. Amyotroph Lateral Scler Other Motor Neuron Dis 2004;4:150-157.
31. Kieran D, Hafezparast M, Bohnert S, et al: A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol 2005;169:561-567.